Jim Cramer Focused On These 9 Stocks Recently

3. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders: 91

During the lightning round, Cramer was asked about Merck & Co., Inc. (NYSE:MRK) and he said:

“Okay, Merck is too cheap. I mean, it’s got a 3.4% yield. Rob Davis is doing very well. It’s really, he’s made a couple acquisitions. I think they’re gonna work out and everyone’s just so scared of the Keytruda patent (the drug has patent protection into 2028) … and that’s not anywhere near. I think you buy the stock of Merck.”

Merck (NYSE:MRK) offers pharmaceutical products in a range of health sectors, such as oncology and vaccines, and also develops veterinary medicines. Additionally, the company partners with other organizations to advance cancer therapies and innovative treatments. In February, discussing the stock being down, Cramer stated:

“Although Merck, is, maybe the ultimate laggard. I don’t think I’ve ever seen Merck perform this badly. Here’s this stock, distinguished from the company, which actually got hurt by a decision by the Chinese to not give their people two hundred million vaccines, GARDASIL, RFK, maybe it’s kind of a reciprocal thing [laughs]. . .it’s great vaccine, you may not like vaccines, but great vaccine, and the, the Chinese have chosen not to use it, they haven’t, and some of it’s with a wholesaler that apparently can’t give anymore to because they don’t have enough money. But that’s the one I’m. . . .that used to be called saint Merck, and I know it’s not high growth anymore but wow, I think it’s worth looking at because it trades like a bad tack.

… No, in the way of what’s really going with some of these drug companies. The loss of, they have a loss of exclusivity for an unbelievable drug KEYTRUDA, but it’s not for years. The only one in this group that acts at all well is Lilly, and I do think that when you’re meeting with the President . . .the drug companies meet with the President and it’s like you don’t know what he’s going to say after.”